By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



500 Old Connecticut Path
Bldg. B
Framingham  Massachusetts  01701  U.S.A.
Phone: 617-588-0083 Fax: n/a


Berg, is a biopharmaceutical company with a research focused on understanding how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early-
stage technologies in CNS diseases and metabolic diseases that complement its late-stage
clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the Berg Interrogative Biology™ discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow.

Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.

For additional information, please visit

Key Statistics

Ownership: Private

Web Site: Berg

Company News
Berg Broadens Relationship With The Department Of Defense (DoD) Center For Prostate Disease Research With New Predictive Biomarker Test For Prostate Cancer 9/19/2017 9:16:28 AM
Berg Presents Key Clinical Data At ESMO 2017 On BPM 31510 For Advanced Pancreatic Cancer Patients And BPM 31543 For Preventing Hair-Loss In Patients Treated With Chemotherapy 9/11/2017 7:27:57 AM
Berg Forms Research Collaboration With AstraZeneca PLC (AZN) To Identify New Therapeutic Targets To Treat Neurological Disorders Such As Parkinson's Disease 8/28/2017 10:37:53 AM
Berg Announces New Partnership With Debra Of America To Tackle Epidermolysis Bullosa-A Rare Genetic Tissue Disorder 5/15/2017 10:05:21 AM
Berg Announces BPM 31510 Data Presentations At 2017 AACR In Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers And Novel Prostate Cancer Biomarker Panel 4/3/2017 8:02:24 AM
Berg Release: New Data Published In Nature Medicine From Joslin Diabetes Center Demonstrates The Importance Of Interrogating Human Biology 3/27/2017 9:47:18 AM
Berg Initiates Phase I/II Monotherapy Trial Of BPM 31510-IV In Patients With Glioblastoma Multiforme (GBM) 2/15/2017 7:41:35 AM
Berg Announces Appointment Of Titus Plattel As Chief Operating Officer 2/7/2017 8:56:17 AM
Berg Release: Company Enters Into Multi-Year Agreement With Becton, Dickinson and Company (BDX) For Next-Generation Analytics In Healthcare IT 1/12/2017 1:24:37 PM
Berg Presents Data Uncovering A Novel Contributor To Parkinson's Disease At Society For Neuroscience 2016 Meeting 11/15/2016 6:45:56 AM